Kancera’s ROR inhibitors show superior efficacy in 3D pancreatic tumor model.
Kancera today announced that its ROR inhibitor show effect in an advanced and challenging human pancreatic cancer model. In the model, the Kancera compounds show superior efficacy compared to gemcitabine, today's most commonly used treatment for pancreatic cancer. The...
Read More